cabergoline Search Results


94
MedChemExpress cabergoline
Toxic function of leflunomide on prolactinoma cell lines. ( A ) MMQ and GH3 cells were incubated with different concentration of leflunomide for 0, 24, 48, or 72 h, and cell proliferation was assessed at different time points by a CCK-8 assay ( n = 6, ± SEM) in each group (GH3: 4 µmol/L Lef vs. 0 µmol/L Lef: ** P = 9.88 × 10 − 4 < 0.01, 10 µmol/L Lef vs. 0 µmol/L Lef: *** P = 5.68 × 10 − 5 < 0.001; MMQ: 2 µmol/L Lef vs. 0 µmol/L Lef: ** P = 7.98 × 10 − 8 < 0.01, 4 µmol/L Lef vs. 0 µmol/L Lef: *** P = 5.40 × 10 − 8 < 0.01, 10 µmol/L Lef vs. 0 µmol/L Lef: *** P = 1.30 × 10 − 9 < 0.001). ( B ) MMQ cells were incubated with/without leflunomide and <t>cabergoline</t> alone or in combination for 0, 24, 48, or 72 h, and cell proliferation was assessed at different time points by a CCK-8 assay ( n = 6, ± SEM; 25 µmol/L Cab vs. 0 µmol/L: * P = 0.001527 < 0.05, 2 µmol/L Lef with 25 µmol/L Cab vs. 0 µmol/L: ** P = 8.32 × 10 − 8 < 0.01). ( C ) Excised tumors in different treatment groups. ( D ) Growth curve showing the changes in the tumor volume in mice after different treatments. (Lef vs. vector: *** P = 1.18 × 10 − 5 < 0.001, Cab vs. vector: *** P = 0.000498 < 0.001, Lef + Cab vs. Cab: *** P = 0.000241 < 0.001, Lef + Cab vs. Lef: * P = 0.002 < 0.05).
Cabergoline, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cabergoline/Cabergoline/pmc11972301-24-0-8
Average 94 stars, based on 1 article reviews
cabergoline - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

93
TargetMol antagonists cabergoline
Toxic function of leflunomide on prolactinoma cell lines. ( A ) MMQ and GH3 cells were incubated with different concentration of leflunomide for 0, 24, 48, or 72 h, and cell proliferation was assessed at different time points by a CCK-8 assay ( n = 6, ± SEM) in each group (GH3: 4 µmol/L Lef vs. 0 µmol/L Lef: ** P = 9.88 × 10 − 4 < 0.01, 10 µmol/L Lef vs. 0 µmol/L Lef: *** P = 5.68 × 10 − 5 < 0.001; MMQ: 2 µmol/L Lef vs. 0 µmol/L Lef: ** P = 7.98 × 10 − 8 < 0.01, 4 µmol/L Lef vs. 0 µmol/L Lef: *** P = 5.40 × 10 − 8 < 0.01, 10 µmol/L Lef vs. 0 µmol/L Lef: *** P = 1.30 × 10 − 9 < 0.001). ( B ) MMQ cells were incubated with/without leflunomide and <t>cabergoline</t> alone or in combination for 0, 24, 48, or 72 h, and cell proliferation was assessed at different time points by a CCK-8 assay ( n = 6, ± SEM; 25 µmol/L Cab vs. 0 µmol/L: * P = 0.001527 < 0.05, 2 µmol/L Lef with 25 µmol/L Cab vs. 0 µmol/L: ** P = 8.32 × 10 − 8 < 0.01). ( C ) Excised tumors in different treatment groups. ( D ) Growth curve showing the changes in the tumor volume in mice after different treatments. (Lef vs. vector: *** P = 1.18 × 10 − 5 < 0.001, Cab vs. vector: *** P = 0.000498 < 0.001, Lef + Cab vs. Cab: *** P = 0.000241 < 0.001, Lef + Cab vs. Lef: * P = 0.002 < 0.05).
Antagonists Cabergoline, supplied by TargetMol, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cabergoline/Cabergoline/pmc12259985-346-1-3
Average 93 stars, based on 1 article reviews
antagonists cabergoline - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

90
Santa Cruz Biotechnology cabergoline
Toxic function of leflunomide on prolactinoma cell lines. ( A ) MMQ and GH3 cells were incubated with different concentration of leflunomide for 0, 24, 48, or 72 h, and cell proliferation was assessed at different time points by a CCK-8 assay ( n = 6, ± SEM) in each group (GH3: 4 µmol/L Lef vs. 0 µmol/L Lef: ** P = 9.88 × 10 − 4 < 0.01, 10 µmol/L Lef vs. 0 µmol/L Lef: *** P = 5.68 × 10 − 5 < 0.001; MMQ: 2 µmol/L Lef vs. 0 µmol/L Lef: ** P = 7.98 × 10 − 8 < 0.01, 4 µmol/L Lef vs. 0 µmol/L Lef: *** P = 5.40 × 10 − 8 < 0.01, 10 µmol/L Lef vs. 0 µmol/L Lef: *** P = 1.30 × 10 − 9 < 0.001). ( B ) MMQ cells were incubated with/without leflunomide and <t>cabergoline</t> alone or in combination for 0, 24, 48, or 72 h, and cell proliferation was assessed at different time points by a CCK-8 assay ( n = 6, ± SEM; 25 µmol/L Cab vs. 0 µmol/L: * P = 0.001527 < 0.05, 2 µmol/L Lef with 25 µmol/L Cab vs. 0 µmol/L: ** P = 8.32 × 10 − 8 < 0.01). ( C ) Excised tumors in different treatment groups. ( D ) Growth curve showing the changes in the tumor volume in mice after different treatments. (Lef vs. vector: *** P = 1.18 × 10 − 5 < 0.001, Cab vs. vector: *** P = 0.000498 < 0.001, Lef + Cab vs. Cab: *** P = 0.000241 < 0.001, Lef + Cab vs. Lef: * P = 0.002 < 0.05).
Cabergoline, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cabergoline/Cabergoline/pmc06694194-244-5-9
Average 90 stars, based on 1 article reviews
cabergoline - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

94
Tocris cabergoline
Toxic function of leflunomide on prolactinoma cell lines. ( A ) MMQ and GH3 cells were incubated with different concentration of leflunomide for 0, 24, 48, or 72 h, and cell proliferation was assessed at different time points by a CCK-8 assay ( n = 6, ± SEM) in each group (GH3: 4 µmol/L Lef vs. 0 µmol/L Lef: ** P = 9.88 × 10 − 4 < 0.01, 10 µmol/L Lef vs. 0 µmol/L Lef: *** P = 5.68 × 10 − 5 < 0.001; MMQ: 2 µmol/L Lef vs. 0 µmol/L Lef: ** P = 7.98 × 10 − 8 < 0.01, 4 µmol/L Lef vs. 0 µmol/L Lef: *** P = 5.40 × 10 − 8 < 0.01, 10 µmol/L Lef vs. 0 µmol/L Lef: *** P = 1.30 × 10 − 9 < 0.001). ( B ) MMQ cells were incubated with/without leflunomide and <t>cabergoline</t> alone or in combination for 0, 24, 48, or 72 h, and cell proliferation was assessed at different time points by a CCK-8 assay ( n = 6, ± SEM; 25 µmol/L Cab vs. 0 µmol/L: * P = 0.001527 < 0.05, 2 µmol/L Lef with 25 µmol/L Cab vs. 0 µmol/L: ** P = 8.32 × 10 − 8 < 0.01). ( C ) Excised tumors in different treatment groups. ( D ) Growth curve showing the changes in the tumor volume in mice after different treatments. (Lef vs. vector: *** P = 1.18 × 10 − 5 < 0.001, Cab vs. vector: *** P = 0.000498 < 0.001, Lef + Cab vs. Cab: *** P = 0.000241 < 0.001, Lef + Cab vs. Lef: * P = 0.002 < 0.05).
Cabergoline, supplied by Tocris, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cabergoline/Cabergoline/pmc12107140__pnas%2E2501229122%2Esapp-15-0-21
Average 94 stars, based on 1 article reviews
cabergoline - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

86
Toronto Research Chemicals cabergoline
Toxic function of leflunomide on prolactinoma cell lines. ( A ) MMQ and GH3 cells were incubated with different concentration of leflunomide for 0, 24, 48, or 72 h, and cell proliferation was assessed at different time points by a CCK-8 assay ( n = 6, ± SEM) in each group (GH3: 4 µmol/L Lef vs. 0 µmol/L Lef: ** P = 9.88 × 10 − 4 < 0.01, 10 µmol/L Lef vs. 0 µmol/L Lef: *** P = 5.68 × 10 − 5 < 0.001; MMQ: 2 µmol/L Lef vs. 0 µmol/L Lef: ** P = 7.98 × 10 − 8 < 0.01, 4 µmol/L Lef vs. 0 µmol/L Lef: *** P = 5.40 × 10 − 8 < 0.01, 10 µmol/L Lef vs. 0 µmol/L Lef: *** P = 1.30 × 10 − 9 < 0.001). ( B ) MMQ cells were incubated with/without leflunomide and <t>cabergoline</t> alone or in combination for 0, 24, 48, or 72 h, and cell proliferation was assessed at different time points by a CCK-8 assay ( n = 6, ± SEM; 25 µmol/L Cab vs. 0 µmol/L: * P = 0.001527 < 0.05, 2 µmol/L Lef with 25 µmol/L Cab vs. 0 µmol/L: ** P = 8.32 × 10 − 8 < 0.01). ( C ) Excised tumors in different treatment groups. ( D ) Growth curve showing the changes in the tumor volume in mice after different treatments. (Lef vs. vector: *** P = 1.18 × 10 − 5 < 0.001, Cab vs. vector: *** P = 0.000498 < 0.001, Lef + Cab vs. Cab: *** P = 0.000241 < 0.001, Lef + Cab vs. Lef: * P = 0.002 < 0.05).
Cabergoline, supplied by Toronto Research Chemicals, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cabergoline/Cabergoline/pmc06331611-238-18-19
Average 86 stars, based on 1 article reviews
cabergoline - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

93
Selleck Chemicals cabergoline
Toxic function of leflunomide on prolactinoma cell lines. ( A ) MMQ and GH3 cells were incubated with different concentration of leflunomide for 0, 24, 48, or 72 h, and cell proliferation was assessed at different time points by a CCK-8 assay ( n = 6, ± SEM) in each group (GH3: 4 µmol/L Lef vs. 0 µmol/L Lef: ** P = 9.88 × 10 − 4 < 0.01, 10 µmol/L Lef vs. 0 µmol/L Lef: *** P = 5.68 × 10 − 5 < 0.001; MMQ: 2 µmol/L Lef vs. 0 µmol/L Lef: ** P = 7.98 × 10 − 8 < 0.01, 4 µmol/L Lef vs. 0 µmol/L Lef: *** P = 5.40 × 10 − 8 < 0.01, 10 µmol/L Lef vs. 0 µmol/L Lef: *** P = 1.30 × 10 − 9 < 0.001). ( B ) MMQ cells were incubated with/without leflunomide and <t>cabergoline</t> alone or in combination for 0, 24, 48, or 72 h, and cell proliferation was assessed at different time points by a CCK-8 assay ( n = 6, ± SEM; 25 µmol/L Cab vs. 0 µmol/L: * P = 0.001527 < 0.05, 2 µmol/L Lef with 25 µmol/L Cab vs. 0 µmol/L: ** P = 8.32 × 10 − 8 < 0.01). ( C ) Excised tumors in different treatment groups. ( D ) Growth curve showing the changes in the tumor volume in mice after different treatments. (Lef vs. vector: *** P = 1.18 × 10 − 5 < 0.001, Cab vs. vector: *** P = 0.000498 < 0.001, Lef + Cab vs. Cab: *** P = 0.000241 < 0.001, Lef + Cab vs. Lef: * P = 0.002 < 0.05).
Cabergoline, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cabergoline/Cabergoline/ppr0511696-104-7-8
Average 93 stars, based on 1 article reviews
cabergoline - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

93
European Directorate for the Quality of Medicines and HealthCare cabergoline
List of seized products and identified active substance(s) in the study.
Cabergoline, supplied by European Directorate for the Quality of Medicines and HealthCare, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cabergoline/Cabergoline+CRS/pmc11962791-153-3-11
Average 93 stars, based on 1 article reviews
cabergoline - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

90
Rameda Pharmaceuticals cabergoline
List of seized products and identified active substance(s) in the study.
Cabergoline, supplied by Rameda Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cabergoline/cabergoline/10__1016_slash_j__mefs__2017__12__008-69-40-43
Average 90 stars, based on 1 article reviews
cabergoline - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Pharmacia Upjohn LLC cabergoline
List of seized products and identified active substance(s) in the study.
Cabergoline, supplied by Pharmacia Upjohn LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cabergoline/cabergoline/pm11502789-75-5-8
Average 90 stars, based on 1 article reviews
cabergoline - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Pfizer Inc cabergoline
Age and in vitro fertilization outcomes of patients according to stimulation protocol
Cabergoline, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cabergoline/cabergoline/pmc05661762-193-7-15
Average 90 stars, based on 1 article reviews
cabergoline - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Pfizer Inc cabergoline dostinex
Age and in vitro fertilization outcomes of patients according to stimulation protocol
Cabergoline Dostinex, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cabergoline/cabergoline+dostinex/pm22296972-104-0-2
Average 90 stars, based on 1 article reviews
cabergoline dostinex - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

Image Search Results


Toxic function of leflunomide on prolactinoma cell lines. ( A ) MMQ and GH3 cells were incubated with different concentration of leflunomide for 0, 24, 48, or 72 h, and cell proliferation was assessed at different time points by a CCK-8 assay ( n = 6, ± SEM) in each group (GH3: 4 µmol/L Lef vs. 0 µmol/L Lef: ** P = 9.88 × 10 − 4 < 0.01, 10 µmol/L Lef vs. 0 µmol/L Lef: *** P = 5.68 × 10 − 5 < 0.001; MMQ: 2 µmol/L Lef vs. 0 µmol/L Lef: ** P = 7.98 × 10 − 8 < 0.01, 4 µmol/L Lef vs. 0 µmol/L Lef: *** P = 5.40 × 10 − 8 < 0.01, 10 µmol/L Lef vs. 0 µmol/L Lef: *** P = 1.30 × 10 − 9 < 0.001). ( B ) MMQ cells were incubated with/without leflunomide and cabergoline alone or in combination for 0, 24, 48, or 72 h, and cell proliferation was assessed at different time points by a CCK-8 assay ( n = 6, ± SEM; 25 µmol/L Cab vs. 0 µmol/L: * P = 0.001527 < 0.05, 2 µmol/L Lef with 25 µmol/L Cab vs. 0 µmol/L: ** P = 8.32 × 10 − 8 < 0.01). ( C ) Excised tumors in different treatment groups. ( D ) Growth curve showing the changes in the tumor volume in mice after different treatments. (Lef vs. vector: *** P = 1.18 × 10 − 5 < 0.001, Cab vs. vector: *** P = 0.000498 < 0.001, Lef + Cab vs. Cab: *** P = 0.000241 < 0.001, Lef + Cab vs. Lef: * P = 0.002 < 0.05).

Journal: Scientific Reports

Article Title: Transcriptomic analysis of the anti-tumor effects of leflunomide in prolactinoma

doi: 10.1038/s41598-025-95509-6

Figure Lengend Snippet: Toxic function of leflunomide on prolactinoma cell lines. ( A ) MMQ and GH3 cells were incubated with different concentration of leflunomide for 0, 24, 48, or 72 h, and cell proliferation was assessed at different time points by a CCK-8 assay ( n = 6, ± SEM) in each group (GH3: 4 µmol/L Lef vs. 0 µmol/L Lef: ** P = 9.88 × 10 − 4 < 0.01, 10 µmol/L Lef vs. 0 µmol/L Lef: *** P = 5.68 × 10 − 5 < 0.001; MMQ: 2 µmol/L Lef vs. 0 µmol/L Lef: ** P = 7.98 × 10 − 8 < 0.01, 4 µmol/L Lef vs. 0 µmol/L Lef: *** P = 5.40 × 10 − 8 < 0.01, 10 µmol/L Lef vs. 0 µmol/L Lef: *** P = 1.30 × 10 − 9 < 0.001). ( B ) MMQ cells were incubated with/without leflunomide and cabergoline alone or in combination for 0, 24, 48, or 72 h, and cell proliferation was assessed at different time points by a CCK-8 assay ( n = 6, ± SEM; 25 µmol/L Cab vs. 0 µmol/L: * P = 0.001527 < 0.05, 2 µmol/L Lef with 25 µmol/L Cab vs. 0 µmol/L: ** P = 8.32 × 10 − 8 < 0.01). ( C ) Excised tumors in different treatment groups. ( D ) Growth curve showing the changes in the tumor volume in mice after different treatments. (Lef vs. vector: *** P = 1.18 × 10 − 5 < 0.001, Cab vs. vector: *** P = 0.000498 < 0.001, Lef + Cab vs. Cab: *** P = 0.000241 < 0.001, Lef + Cab vs. Lef: * P = 0.002 < 0.05).

Article Snippet: Cabergoline (HY-15296) and leflunomide (HY-B0083) were purchased from MedChemExpress and dissolved in dimethyl sulfoxide (DMSO).

Techniques: Incubation, Concentration Assay, CCK-8 Assay, Plasmid Preparation

Functional role of important differentially expressed genes (DEGs) associated with cabergoline and combination drugs. ( A ) Heatmap of DEGs in cabergoline. ( B ) Gene Ontology (GO) and pathway enrichment of DEGs related to cabergoline use; nodes: enrichment terms; terms ranked by significant P -values. ( C ) Module analysis of the Protein–Protein Interaction (PPI) network created with Metascape ( https://metascape.org/gp/index.html#/main/step1 ). ( D ) Transcription factor (TF)-regulated network in cabergoline; red nodes: up-regulated DEGs, green nodes: down-regulated genes. (E) DEGs between cabergoline combined drugs. ( F ) GO and pathway enrichment of DEGs between cabergoline and combined drugs.

Journal: Scientific Reports

Article Title: Transcriptomic analysis of the anti-tumor effects of leflunomide in prolactinoma

doi: 10.1038/s41598-025-95509-6

Figure Lengend Snippet: Functional role of important differentially expressed genes (DEGs) associated with cabergoline and combination drugs. ( A ) Heatmap of DEGs in cabergoline. ( B ) Gene Ontology (GO) and pathway enrichment of DEGs related to cabergoline use; nodes: enrichment terms; terms ranked by significant P -values. ( C ) Module analysis of the Protein–Protein Interaction (PPI) network created with Metascape ( https://metascape.org/gp/index.html#/main/step1 ). ( D ) Transcription factor (TF)-regulated network in cabergoline; red nodes: up-regulated DEGs, green nodes: down-regulated genes. (E) DEGs between cabergoline combined drugs. ( F ) GO and pathway enrichment of DEGs between cabergoline and combined drugs.

Article Snippet: Cabergoline (HY-15296) and leflunomide (HY-B0083) were purchased from MedChemExpress and dissolved in dimethyl sulfoxide (DMSO).

Techniques: Functional Assay

List of seized products and identified active substance(s) in the study.

Journal: Frontiers in Chemistry

Article Title: Illegal and falsified medicines self-administrated in not approved post-cycle therapy after the cessation of anabolic-androgenic steroids – qualitative analysis

doi: 10.3389/fchem.2025.1536858

Figure Lengend Snippet: List of seized products and identified active substance(s) in the study.

Article Snippet: Reference standards: anastrozole, cabergoline, clomiphene citrate, letrozole, mesterolone, and raloxifene hydrochloride (EDQM, Strasbourg, France); tamoxifen citrate (Sigma Aldrich, Saint Louis, MO, United States); exemestane (USP, Rockville, MD, United States); EDTA (Chempur, Piekary Śląskie, Poland); WHO International Standard for hCG; and medicinal product Pregnyl (N.V. Organon, Netherlands).

Techniques: Labeling

Extracted-ion chromatogram (ESI+) of the sample with cabergoline and stanozolol; product ion spectrum of cabergoline.

Journal: Frontiers in Chemistry

Article Title: Illegal and falsified medicines self-administrated in not approved post-cycle therapy after the cessation of anabolic-androgenic steroids – qualitative analysis

doi: 10.3389/fchem.2025.1536858

Figure Lengend Snippet: Extracted-ion chromatogram (ESI+) of the sample with cabergoline and stanozolol; product ion spectrum of cabergoline.

Article Snippet: Reference standards: anastrozole, cabergoline, clomiphene citrate, letrozole, mesterolone, and raloxifene hydrochloride (EDQM, Strasbourg, France); tamoxifen citrate (Sigma Aldrich, Saint Louis, MO, United States); exemestane (USP, Rockville, MD, United States); EDTA (Chempur, Piekary Śląskie, Poland); WHO International Standard for hCG; and medicinal product Pregnyl (N.V. Organon, Netherlands).

Techniques:

Age and in vitro fertilization outcomes of patients according to stimulation protocol

Journal: Reproductive Medicine and Biology

Article Title: Cabergoline administration prevents development of moderate to severe ovarian hyperstimulation syndrome and it contributes to reduction in ovarian volume

doi: 10.1007/s12522-014-0198-9

Figure Lengend Snippet: Age and in vitro fertilization outcomes of patients according to stimulation protocol

Article Snippet: It is known that the half‐time of cabergoline can be as long as 43 h (Pfizer Inc., New York, NY, USA); therefore this agent is usually administered weekly for the treatment of hyperprolactinemia [ 19 ].

Techniques: In Vitro, Control

OHSS incidence and its parameters in patients with each stimulation protocol

Journal: Reproductive Medicine and Biology

Article Title: Cabergoline administration prevents development of moderate to severe ovarian hyperstimulation syndrome and it contributes to reduction in ovarian volume

doi: 10.1007/s12522-014-0198-9

Figure Lengend Snippet: OHSS incidence and its parameters in patients with each stimulation protocol

Article Snippet: It is known that the half‐time of cabergoline can be as long as 43 h (Pfizer Inc., New York, NY, USA); therefore this agent is usually administered weekly for the treatment of hyperprolactinemia [ 19 ].

Techniques: Control